Novo Nordisk
NVO
$122.71
Share price
-0.03%
Change (1 day)
44.55%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) - Total debt
Total debt on the balance sheet as of December 2023 : $3.99 B
According to Novo Nordisk's latest financial reports the company's total debt is $3.99 B. A company’s total debt is the sum of all current and non-current debts.
Novo Nordisk - Total debt on balance sheet (from 2001 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $3.99 B | 7.72% |
| 2022-12-31 | $3.71 B | -8.47% |
| 2021-12-31 | $4.05 B | 136.98% |
| 2020-12-31 | $1.71 B | 154.68% |
| 2019-12-31 | $0.67 B | 751.86% |
| 2018-12-31 | $78.9 M | -71.11% |
| 2017-12-31 | $0.27 B | 742.26% |
| 2016-12-31 | $32.42 M | -79.38% |
| 2015-12-31 | $0.15 B | 33.71% |
| 2014-12-31 | $0.11 B | 195.43% |
| 2013-12-31 | $39.8 M | -55.1% |
| 2012-12-31 | $88.65 M | -40.34% |
| 2011-12-31 | $0.14 B | -62.56% |
| 2010-12-31 | $0.39 B | 48.44% |
| 2009-12-31 | $0.26 B | -38.67% |
| 2008-12-31 | $0.43 B | 63.14% |
| 2007-12-31 | $0.26 B | -0.48% |
| 2006-12-31 | $0.26 B | -37% |
| 2005-12-31 | $0.42 B | 37.18% |
| 2004-12-31 | $0.31 B | 6.04% |
| 2003-12-31 | $0.29 B | 47.86% |
| 2002-12-31 | $0.19 B | -17.79% |
| 2001-12-31 | $0.24 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 1,671.28% | 🇺🇸 USA |
 Eli Lilly LLY | $25.22 B | 530.69% | 🇺🇸 USA |
 Sanofi SNY | $20.36 B | 409.22% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | $41.46 B | 936.69% | 🇺🇸 USA |